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Abstract
Background: A disrupted cell cycle progression of hepatocytes was reported in chronic hepatitis
C virus (HCV) infection, which can contribute significantly in the associated pathogenesis. The
present study aimed to further elaborate these disruptions by evaluating the expression of key cell
cycle and apoptotic proteins in chronic HCV infection with particular reference to genotype 3.
Archival liver biopsy specimens of chronic HCV-infection (n = 46) and normal histology (n = 5)
were analyzed by immunohistochemistry using antibodies against proliferation marker Mcm-2, G1
phase marker Cyclin D1, S phase marker Cyclin A, cell cycle regulators p21 (CDK inhibitor) and
p53 (tumor suppressor protein), apoptotic protein Caspase-3 and anti-apoptotic protein Bcl-2.
Results: Elevated Mcm-2 expression was observed in hepatocytes in chronic HCV infection,
indicating increased cell cycle entry. Cyclin D1 expression was higher than cyclin A, which suggests
a slow progression through the G1 phase. Expression of cell cycle regulators p21 and p53 was
elevated, with no concordance between their expressions. The Mcm-2 and p21 expressions were
associated with the fibrosis stage (p = 0.0001 and 0.001 respectively) and that of p53 with the
inflammation grade (p = 0.051). Apoptotic marker, Caspase-3, was mostly confined to sinusoidal
lining cells with little expression in hepatocytes. Anti-apoptotic protein, Bcl-2, was negligible in
hepatocytes and detected principally in infiltrating lymphocytes. Expression of all these proteins
was unrelated to the HCV genotype and were detected only rarely in the hepatocytes of normal
liver.
Conclusion: The results showed an arrested cell cycle state in the hepatocytes of chronic HCV
infection, regardless of any association with genotype 3. Cell cycle arrest is characterized by an
increased expression of p21, in relation to fibrosis, and of p53 in relation to inflammation.
Furthermore, expression of p21 was independent of the p53 expression and coincided with the
reduced expression of apoptotic protein Caspase-3 in hepatocytes. The altered expression of these
cell cycle proteins in hepatocytes is suggestive of an impaired cell cycle progression that could limit
the regenerative response of the liver to ongoing injury, leading to the progression of disease.
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Background
Hepatitis C virus (HCV) infections account for a vast
majority of viral hepatitis cases in some geographical
areas. In Pakistan, around 6% of people are estimated to
be infected with HCV [1]. These figures are alarming, since
patients currently asymptomatic with relatively mild dis-
ease will eventually progress to the end-stage liver disease
and develop hepatocellular carcinoma (HCC). Currently,
there is no vaccine against HCV and antiviral treatment is
not only expensive but relatively toxic and is sufficiently
ineffective in treating all of the patients [2]. This under-
scores the need for more effective therapies. A better
understanding of the molecular mechanisms underlying
the pathology of chronic HCV infections could be helpful
in identifying novel therapeutic targets against this dis-
ease.
The hallmarks of chronic HCV infection in the liver are
inflammation, necrosis, hepatocellular damage and fibro-
sis. The damage caused by inflammation and necrosis
leads generally to proliferation of the remaining hepato-
cytes, a characteristic of liver regeneration [3]. Prolifera-
tive responses of hepatocytes to HCV infection are
particularly important in subsequent pathogenesis as
hepatocytes are the primary site of HCV replication and
receive different cellular stresses from lymphocytes and
Kupffer cells. Several studies have measured proliferative
activity in liver tissue from patients with chronic HCV
infection using a variety of markers such as Ki-67, prolif-
erating cell nuclear antigen (PCNA) and mini-chromo-
some maintenance protein-2 (Mcm-2) [4-6]. Among
these, Mcm-2 has been documented as a more sensitive
proliferation marker than Ki-67 in chronic HCV-infected
patients [5].
The molecular events during proliferation are related
closely to the cell cycle and its regulation. When stimu-
lated to proliferate, hepatocytes first enter the G1 phase of
the cell division cycle which is followed by DNA synthe-
sis, or the S phase. Progression through each phase of the
cell cycle involves periodic activation of phase-specific
protein kinase complexes comprising of cyclins and cyclin
dependent kinases (CDKs). Therefore, cyclin D-CDK4/
CDK6 complex is activated in the G1 phase and cyclin A-
CDK2 is activated in the S phase [7,8]. Cyclin-CDK com-
plexes are known to be regulated negatively by CDK
inhibitors (CKIs), which are induced in response to differ-
ent stimuli including DNA damage and oxidative stress.
One such inhibitor is the p21WAF1/CIP1 (p21) protein that
binds to various cyclin-CDK complexes and inhibits the
activity of CDK in both p53-dependent and p53-inde-
pendent fashion [9,10]. Both p53 and p21 may be of rel-
evance while studying the HCV induced disease
mechanism, as a number of viral proteins modulate p53
and p21 expression and activity in vitro [11,12]. Besides a
role in cell cycle regulation, p53 also activates and
represses various genes involved in apoptosis, including
the gene for pro-apoptotic protein Bax and anti-apoptotic
protein Bcl-2 [13].
A number of ex vivo studies revealed that the expression of
HCV proteins in cultured cells modulates normal cell
cycle regulation and apoptosis [14,15]. Similarly, studies
of liver specimens from patients with chronic HCV infec-
tion have also shown impaired hepatocyte proliferation
[16] and enhanced apoptosis [17] that may play a role in
the subsequent pathogenesis. A recent study has shown
marked differences in the phase-distribution of cycling
hepatocytes using immunohistochemical staining [18],
with a striking reduction in the markers of late cell cycle
phases (i.e. the S phase and beyond) consistent with G1
arrest. Moreover, impaired proliferation of hepatocytes
has been implicated in the development of cirrhosis [19],
suggesting the involvement of cell cycle machinery in liver
disease progression. Evaluation of the expression of key
proteins related to the cell cycle and apoptosis in chroni-
cally infected patients with HCV would be of significance
to understand disease pathogenesis, and will help in iden-
tifying novel prognostic indicators.
In the present study, we aimed to evaluate the expression
of cell cycle and apoptotic proteins in chronic HCV-
infected patients. The majority (69%) of patients included
in our study were infected by HCV genotype-3 (GT-3).
Such patients are known to have a high prevalence of stea-
tosis [20], which might influence the hepatocyte replica-
tion pathway. Therefore, we examined whether the
proliferation and cell cycle progression of hepatocytes is
different in GT-3 infected patients as compared to other
genotypes. The results indicate an arrested cell cycle state
in hepatocytes, as revealed by the reduced expression of S
phase cyclin and the increased expression of the G1 inhib-
itor p21. Further, no association between the expression
of cell cycle regulator p21 and that of p53 was found.
Finally, the analysis of apoptosis related proteins Caspase-
3 and anti-apoptotic Bcl-2 expression in the same set of
biopsies revealed minimal expression in hepatocytes.
Results
Expression of Mcm-2 and cyclins in hepatocytes
The proliferative potential of hepatocytes was examined
by immunostaining for Mcm-2 that identifies replicating
cells as well as cells that are arrested in the cell cycle [21].
Increased expression of Mcm-2 was observed in HCV-
infected liver tissues (see Additional file 1, median (range)
= 11% (1.5 – 29.6)) with no significant difference
between the genotype 3 and others (1 and 4). In normal
liver tissue its expression was less than 0.01%. Interest-
ingly, a significant increase in Mcm-2 expression wasBMC Microbiology 2008, 8:133 http://www.biomedcentral.com/1471-2180/8/133
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found with the progression of the fibrosis stage (Figure 1,
Jonckheere-Terpstra test, p = 0.0001).
Analysis of cell cycle phase markers in patients with
chronic HCV infection revealed that the proportion of
Mcm-2 hepatocytes expressing cyclin D1 (G1 phase
marker) was 35% (3 – 54), which was significantly higher
than that for cyclin A (S phase marker) (4.0% (0.1 – 18),
Mann-Whitney U test, p = 0.0001). In normal liver tissues,
Cyclin D and A expression was minimal.
Expression of cell cycle regulators p21 and p53
In normal liver tissues very low expression (< 0.01%) of
cell cycle regulator p21 was observed, whereas 78% (36/
46) of patients with chronic HCV infection showed
increased expression (Figure 2) with a median (range) of
9.3% (1.0 – 19.5). p53 was also expressed rarely (<
0.01%) in normal liver tissues. In comparison, 52% (24/
46) of patients with chronic HCV infection had enhanced
expression of p53 (Figure 3) with a median (range) of
8.5% (1.0 – 15.6). Of these, 33% (15/46) expressed both
p53 and p21, with no correlation between their expres-
sion (Spearman rank correlation, p = 0.38). p21 positive
hepatocyte expression correlated with progression of the
fibrosis stages (Figure 1, Jonckheere Terpstra, p = 0.001)
but not with the inflammation grade. In contrast, p53
expression was found to be associated weakly with the
inflammation grade (Jonckheere Terpstra test, p = 0.051),
but not with the fibrosis stage. No significant association
was found between these regulators and the degree of
steatosis. Similarly, no difference in their expression levels
was noted in GT-3 patients when compared to patients
infected with other genotypes.
Expression of apoptosis proteins
Expression of the two apoptotic proteins Caspase-3 and
Bcl-2, which are involved in apoptosis execution and anti-
apoptotic functions, respectively, were assessed. Caspase-
3 was detected in 43% of the patients, and was expressed
principally within sinusoidal lining cells, including
endothelial cells and Kupffer cells (Figure 4a). In hepato-
cytes its expression was relatively low, with a median
(range) of 1.8% (0.1–3.2), while no correlation was
found between Caspase-3 and cell cycle regulators or with
any of the histological features.
Expression of Bcl-2 was either negative or negligible in the
hepatocytes of HCV-infected patients, but was more
apparent in other cell types including inflammatory cells
and sinusoidal lymphocytes (Figure 4b). In normal liver
tissues, both caspase-3 and Bcl-2 were rarely detected.
Discussion
In the present study, we have examined the expression of
cell cycle proteins with particular reference to HCV GT-3.
Our results provide evidence of p21-mediated hepatocyte
cell cycle arrest in chronic HCV-infected patients regard-
less of any association with GT-3. A previous report by
Marshall et al has also shown G1 arrest in hepatocytes
using the same cell cycle markers in a different set of
patients [18]. We broadened the focus of our study by pro-
viding indirect evidence that p21 expression was inde-
pendent of p53 expression. Furthermore, minimal
expression of the apoptosis related protein Caspase-3 was
observed in hepatocytes which were without any detecta-
ble expression of anti-apoptotic Bcl-2.
In the initial phases of chronic liver disease, hepatocytes
proliferate to restore liver mass and maintain hepatic
function [22,23]. Consistent with this principle, we found
an increased number of hepatocytes expressing the cell
proliferation marker, Mcm-2. However, the ongoing
inflammation and injury causes disruptions in cell cycle
progression. These disruptions are evidenced in the
present study by decreased expression of S phase cyclin
(Cyclin A) and increased expression of p21. Moreover, the
expression of these proteins did not differ significantly in
genotype 3 infected patients when compared to other gen-
otypes. This indicates that HCV GT-3 has no peculiar
effect on hepatocyte cell cycle disruption, though a signif-
icant difference is observed in its response to the treat-
ment and development of steatosis [20]. Nevertheless, it
can not be neglected that this comparison was made on a
small group of patients and further studies to analyze the
relevance of the HCV genotype with cell cycle disruption
are needed.
Expression of both p21 and Mcm-2 proteins in hepato-
cytes showed a positive association with the progression
Hepatocyte expression of cell cycle proteins and apoptotic  marker in chronic hepatitis C patients with respect to fibro- sis stage Figure 1
Hepatocyte expression of cell cycle proteins and 
apoptotic marker in chronic hepatitis C patients with 
respect to fibrosis stage. * = p-value ≤ 0.05.
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Expression of cell cycle regulator p21 Figure 2
Expression of cell cycle regulator p21. Nuclear expression of p21 in hepatocytes of chronic hepatitis C patients, fibrosis 
stage 2 (F2) and 4 (F4) (Mayer hematoxylin, magnification 400×).
F2
F4BMC Microbiology 2008, 8:133 http://www.biomedcentral.com/1471-2180/8/133
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Expression of cell cycle regulator p53 Figure 3
Expression of cell cycle regulator p53. Nuclear p53 expression in liver biopsy specimens from chronic hepatitis C patient, 
grade 1 (G1) and 3 (G3) (Mayer hematoxylin, magnification 400×).
G1
G3BMC Microbiology 2008, 8:133 http://www.biomedcentral.com/1471-2180/8/133
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Apoptotic activity in hepatocytes of Hepatitis C patients Figure 4
Apoptotic activity in hepatocytes of Hepatitis C patients. Immunostaining in liver biopsies of chronic hepatitis C 
patient (HCV). a) Caspase-3 expression was observed principally in sinusoidal lining cells (arrow) and rarely in hepatocytes 
(arrow head), b) Bcl-2 staining observed in inflammatory cells, (magnification 400×).
a) 
b) BMC Microbiology 2008, 8:133 http://www.biomedcentral.com/1471-2180/8/133
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of fibrosis. This brings into focus the relationship of hepa-
tocyte proliferation and cell cycle arrest with changes tak-
ing place in the extra cellular matrix. It also supports
previous observations reported by Clouston et al which
suggested that hepatocyte replicative arrest drives the bile
ductular reaction and fibrosis in chronic HCV infected
patients [24].
Although the association of p21 with hepatocyte replica-
tive arrest and disease activity has been described in
chronic hepatitis C patients [18,24], it is not known as to
whether this increase is due to up-regulation of p53 or
some other mechanism. We investigated this aspect by
evaluating p53 expression in the same set of biopsies and
found that both p53 and p21 co-expressed in only 33%
[1/3] of the patients, but their expression did not correlate
with each other. This indicates that p21 expression in
hepatocytes during chronic HCV infection is probably
mediated through p53-independent mechanisms involv-
ing TGF-β [10] and oxidative stress [25]. On the other
hand, HCV might also be involved in manipulating the
expression of these cell cycle regulators, as observed in
vitro  following ectopic expression of viral proteins
[11,26]. Nonetheless, direct evidence of these virus-
induced manipulations in chronic HCV infection is still
lacking in literature.
In normal conditions p53 expression remains undetecta-
ble by immunohistochemistry. However, exposure to a
variety of cellular stresses leads either to an increased syn-
thesis rate of wild type p53 or the production of a mutated
p53 with increased stability that would become detectable
by immunohistochemistry. We observed an accumulation
of p53 in the hepatocytes of chronic HCV patients with a
significant percentage in the advanced stages of fibrosis.
This is consistent with a previous report by Papakyriakou
et al [27] that has shown p53 expression in severe viral
hepatitis. But whether this accumulation of p53 is due to
the increased synthesis or the production of mutated p53
is not yet determined. We also observed an association of
p53 expression with a grade of inflammation that was
marginally significant (p = 0.051). Accumulation of p53
in response to inflammatory stress [28] as well as it's con-
tribution to inflammation-induced injury is also noted in
published data [29,30]. This could be due to the increased
production of reactive oxygen species during inflamma-
tion that can directly cause DNA damage [31] and thus
p53 activation [32].
Since hepatocyte proliferation plays an important role in
the regenerative response to hepatic damage, a replicative
arrest in hepatocytes could, therefore, impair the regener-
ative response of the liver to the ongoing injury. In fact,
experiments in knock out mice have shown a significant
contribution of the p53/p21 system in the impairment of
liver regeneration following partial hepatectomy [33].
This in turn contributes to the pathogenesis of cirrhosis
and hepatocellular carcinoma. Moreover, impaired cell
cycle kinetics could also lead to the activation of the apop-
tosis pathway to preserve cell viability and genetic integ-
rity. Studies on hepatic biopsies have shown a variable
degree of apoptosis in HCV infected patients ranging from
0.54%–20%, depending on the method used [34]. Some
of these studies have also shown a correlation of apopto-
sis with liver pathology, but the mechanisms involved
were not well defined. In our present study, we analyzed
the apoptotic activity by examining the expression of Cas-
pase-3, a downstream effector molecule in the apoptotic
pathway. Caspase-3 has been shown to be involved in p21
cleavage and the subsequent translocation to cytoplasm in
a p53-dependent manner [35]. Our results revealed a
minor expression of Caspase-3 in hepatocytes, while the
p21 antigen was apparent in the nucleus of hepatocytes.
Based on these observations, we contemplate that the
increased expression of p21 in hepatocytes is probably
responsible for the reduced expression of Caspase-3 in
hepatocytes. The inhibitory role of p21 in the apoptotic
pathway has been documented previously by several
investigators [36,37]. On the other hand, our results differ
with a previous report by Bental et al which showed high
Caspase-3 expression in the hepatocytes of chronic hepa-
titis C patients [38]. Possible explanations for this discrep-
ancy could be the different antibodies and sample size
used, along with the high prevalence of genotype 3
infected patients in our study. We further examined if the
low apoptotic index in hepatocytes is due to the high lev-
els of Bcl-2. Interestingly, Bcl-2 expression was mainly
observed in mononuclear/inflammatory cells but not in
hepatocytes, suggesting that the reduced apoptosis in
hepatocytes is not due to the anti-apoptotic activity of Bcl-
2.
Conclusion
Our analysis of the cell cycle and apoptotic proteins dur-
ing chronic HCV infection has shown an impaired prolif-
eration of hepatocytes, which is characterized by
increased expression of p21 and p53. Furthermore,
increased nuclear expression of p21 in hepatocytes coin-
cides with the minimal expression of the apoptotic pro-
tein Caspase-3 and the anti-apoptotic Bcl2. In the scenario
of HCV-associated liver inflammation, an altered expres-
sion of these cell cycle proteins will probably reduce the
number of replicating hepatocytes that can limit the
regenerative response of the liver. The present work there-
fore, offers a broader aspect to understand the mecha-
nisms involved in the pathogenesis of HCV infection.BMC Microbiology 2008, 8:133 http://www.biomedcentral.com/1471-2180/8/133
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Methods
Liver biopsy samples and histology
After obtaining approval from the ethical review commit-
tee of Aga Khan University, paraffin-embedded liver
biopsy specimens were studied from forty-six untreated
patients with chronic HCV infection. All patients were
HCV antibody positive, as determined by a commercially
available enzyme-linked immunosorbent assay kit
(Abbott Laboratories, Chicago, IL). Patients having other
etiologies for chronic liver disease including HBV infec-
tion were not included in the study. Histopathological
grading and staging was performed on formalin-fixed tis-
sue samples by an experienced liver pathologist according
to the Batts and Ludwig scoring system [39] at the His-
topathology laboratory of Aga Khan University. Steatosis
was assessed by the same pathologist using the Brunt scor-
ing system [40]. The demographic features of the patients
are given in Table 1. Liver biopsy specimens from five con-
trol patients were also included in the study. These were
selected on the basis of a normal histology as determined
by light microscopy. None had evidence of acute or
chronic liver disease and all were negative for both anti-
HCV antibodies and HCV-RNA.
Antibodies
Mouse monoclonal antibodies to cyclin D1 (DSC-6,
1:40), p21 (cyclin dependent kinase inhibitor, SX-118,
1:40), p53 (tumor suppressor protein, DO-7, 1:40) and
Bcl-2 (anti-apoptotic protein, Klon-124, 1:50) were pur-
chased from DAKO (Denmark). Caspase-3 (apoptotic
marker, E-8, 1:100) was purchased from Santa Cruz (CA)
and cyclin A (6E6, 1:50) from Novacastra (MA). The
Mcm-2 antibody (CRCT2.1, 1:50) was a gift from Abcam
(UK).
Immunohistochemistry
For immunohistochemistry 4-μm sections of paraffin-
embedded liver tissues were de-paraffinized and rehy-
drated using a xylene-alcohol sequential wash. Following
this, all sections were subjected to antigen retrieval by
heating in 0.01 M citrate buffer (pH 6.0) in a pressure-
cooker. This was followed by endogenous peroxidase
ablation using 0.6% hydrogen peroxide in methanol.
After blocking with 10% goat serum for two hours, the
sections were incubated with primary antibodies over-
night at 4°C. The slides were subsequently incubated, first
with biotinylated secondary antibodies and then with the
labeled ABC (streptavidin horseradish peroxidase detec-
tion system, DAKO) using diaminobenzidine (Sigma) as
a substrate. Finally, the slides were counterstained with
haematoxylin and mounted in DPEX for examination.
Positive controls were included in each batch of the slides
and negative controls were obtained by omitting the pri-
mary antibodies.
Quantitative analysis
The immuno-stained sections were examined using a
Nikon Eclipse E8000 and an image analysis system,
(Nikon, Japan). Evaluations of Mcm-2, cyclin D, cyclin A,
p21 and p53 expression were based on nuclear staining;
Caspase-3 expression was assessed by both cytoplasmic
and nuclear staining while Bcl-2 expression was assessed
by membranous staining. Quantification of positive
hepatocytes was undertaken by two independent observ-
ers by counting approximately 1000 hepatocytes at mag-
nification 400× in five randomly selected fields. The
positive hepatocytes were expressed as a percentage of the
total cells counted in each case and values for the subse-
quent analysis were obtained from the mean of the two
independent observations. In the case of Mcm-2, p21, p53
and Caspase-3 this was defined as the labeling index (LI).
For cyclin D and cyclin A, positive hepatocytes were
expressed as a percentage of the number of hepatocytes
expressing Mcm-2 for each case and defined as the labe-
ling fractions (LF) [18].
Statistical Analysis
Data analyses were performed using the Statistical Pack-
age for Social Sciences (SPSS, 14.0). Associations between
the expression of Mcm-2, p21, p53 or Caspase-3 with the
histological features (stage of fibrosis, grade of inflamma-
tion and steatosis) were analyzed using the Jonckheere-
Terpstra test. To determine the differences in the expres-
sion of cell cycle proteins between genotype groups, the
Mann-Whitney U test was used. Correlations among cyc-
Table 1: Demographic and clinical features of the patients
No. of patients 46
Age (years) 42+9.3
Gender (male) 77%
Viral genotype
36 3 . 0 %
Other genotypes (1 or 4) 19.6%
*NA 17.4%
Stage of Fibrosis (0–4), n
09
11 0
21 3
37
47
Grade of Inflammation, (0–4), n
06
18
21 7
31 5
Steatosis, n
None 25
Mild 6
Moderate 9
Severe 4
*Not availableBMC Microbiology 2008, 8:133 http://www.biomedcentral.com/1471-2180/8/133
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lin D1 – cyclin A and p21 – p53 were evaluated by the
Spearman's rank correlation coefficient. A p-value of ≤
0.05 was considered significant.
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